Shows / Lymphoma Hub

Lymphoma Hub
The Lymphoma Hub is an open-access online resource, dedicated to providing balanced, credible, and up-to-date medical education in lymphoma and CLL. Our aim is to enhance knowledge in lymphoma and CLL, through the multichannel dissemination of global advances related to their classification, diagnosis, treatment, and management.
Hosted on Acast. See acast.com/privacy for more information.
Episodes
Lymphoma HubWhat are the key considerations when delivering 1L treatment for AS cHL and how can AEs be managed?
The Lymphoma Hub was pleased to speak to Graham Collins, Oxford University Hospitals, UK. We asked, What are the key considerations when delivering 1L…
Lymphoma HubHow do you see tandem CAR T-cell therapies fitting into the future treatment landscape for LBCL?
The Lymphoma Hub was pleased to speak with Ulrich Jäger, Medical University of Vienna, AT. We asked, How do you see tandem CAR T-cell therapies fitting into…
Lymphoma HubWhat do the 3-year follow-up results from the STARGLO trial tell us about Glofit-GemOx in R/R DLBCL?
The Lymphoma Hub was pleased to speak with Christopher P. Fox, University of Nottingham, UK. We asked, What do the 3-year follow-up results from the STARGLO…
Lymphoma HubHow might key findings from the HD21 trial influence 1L treatment of advanced stage cHL?
The Lymphoma Hub was pleased to speak to Peter Borchmann, University Hospital Cologne, Cologne, DE. We asked, How might key findings from the HD21 trial…
Lymphoma HubWhat is the current clinical evidence for tandem CAR T-cell therapies in R/R DLBCL?
The Lymphoma Hub was pleased to speak to Nirav Shah, Medical College of Wisconsin, Milwaukee, US. We asked, What is the current clinical evidence for tandem…
Lymphoma HubWhat is the rationale for the development of tandem CAR T-cell therapies?
The Lymphoma Hub was pleased to speak with Peter Borchmann, University Hospital Cologne, DE. We asked, What is the rationale for the development of tandem…
Lymphoma HubSymposium |Optimizing chronic lymphocytic leukemia management in a changing landscape
On June 22, 2026, the Lymphoma Hub held a virtual symposium, titled Optimizing treatment for chronic lymphocytic leukemia with BTK inhibitors. During the…
Lymphoma HubSymposium | BTK inhibitors in practice: Treatment selection and emerging clinical evidence
On June 22, 2026, the Lymphoma Hub held a virtual symposium, titled Optimizing treatment for chronic lymphocytic leukemia with BTK inhibitors. During the…
Lymphoma HubSymposium | BTK inhibitors in CLL: Mechanisms, clinical considerations, and unmet needs
On June 22, 2026, the Lymphoma Hub held a virtual symposium, titled Optimizing treatment for chronic lymphocytic leukemia with BTK inhibitors. During the…
Lymphoma HubEHA 2026 | What are the key findings from the DALY 2-EU trial of zamto-cel in R/R LBCL?
The Lymphoma Hub was pleased to speak with Gloria Iacoboni, Vall d'Hebron University Hospital, Barcelona, ES. We asked, What are the key findings from the DALY…
Lymphoma HubEHA2026 | What are the key findings from the subgroup analysis of the EPCORE FL-1 trial in R/R FL?
Following the European Hematology Association (EHA) 2026 Congress, June 11–14, 2026, Stockholm, SE, the Lymphoma Hub spoke with Lorenzo Falchi, Memorial Sloan…
Lymphoma HubZanubrutinib for patients with previously untreated CLL/SLL: Insights from the SEQUOIA trial
During the Lymphoma Hub Steering Committee Meeting on April 20, 2026, key opinion leaders met to discuss results from the long-term follow-up of the phase III…
Lymphoma HubEHA 2026 | What are the key findings from the phase I ANTLER trial in R/R B-cell NHL?
During the European Hematology Association (EHA) 2026 Congress, June 11–14, 2025, Stockholm, SE, the Lymphoma Hub spoke with Stephen Schuster, University of…
Lymphoma HubAnnual oncology meeting | Key highlights in lymphoma
During the American Society of Clinical Oncology Annual Meeting, May 19 – June 2, 2026, Chicago, US, the Lymphoma Hub was pleased to speak with Joshua Brody…
Lymphoma HubEHA 2026 | What are the most recent findings from the phase I NX-5948-301 trial evaluating bexobrutideg in CLL?
During the 31st European Hematology Association (EHA) Congress, June 11–14, 2025, Stockholm, SE, the Lymphoma Hub spoke with Dr. Talha Munir, Leeds Teaching…
Lymphoma HubASH 2025 | Key highlights in lymphoma and CLL
During the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, December 6–9, 2025, Orlando, US, the Lymphoma Hub was pleased to speak with…
Lymphoma HubASH 2025 | Latest updates from the phase I NX-5948-301 trial of bexobrutideg in patients with R/R CLL
During the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, December 6–9, 2025, Orlando, US, the Lymphoma Hub was pleased to speak with…
Lymphoma HubWhat do the clinical data tell us about fixed-duration ibrutinib + venetoclax for patients with CLL?
The Lymphoma Hub was pleased to speak to Susan O’Brien, Chao Family Comprehensive Cancer Center, University of California, Irvine, US. We asked, What do the…
Lymphoma HubASH 2025 | EPCORE FL-1 phase III primary results: Epcoritamab with rituximab + lenalidomide (R2) vs R2 alone for R/R FL
During the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, December 6–9, 2025, Orlando, US, the Lymphoma Hub was pleased to speak with…
Lymphoma HubASH 2025 | 3-year follow-up results from the STARGLO trial of Glofit-GemOx vs R-GemOx in R/R DLBCL
During the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, December 6–9, 2025, Orlando, US, the Lymphoma Hub was pleased to speak with…
Lymphoma HubASH 2025 | Epcoritamab for R/R DLBCL: Results from EPCORE NHL-6, by race and ethnicity
During the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, December 6–9, 2025, Orlando, US, the Lymphoma Hub was pleased to speak with…
Lymphoma HubGlofit-GemOx vs R-GemOx in patients with R/R DLBCL: Results from the STARGLO trial
During the Lymphoma Hub Steering Committee Meeting on October 6, 2025, key opinion leaders met to discuss the results from the phase III STARGLO trial…
Lymphoma HubWhat factors influence BTKi + BCL-2i treatment selection for patients with CLL?
The Lymphoma Hub was pleased to speak to Francesc Bosch, Vall d'Hebron Barcelona Hospital Campus, Barcelona, ES. We asked, what factors influence Bruton’s…
Lymphoma HubLatest updates from the phase III STARGLO trial: 2L and 3L+ data
The Lymphoma Hub was pleased to speak to Charles Herbaux, University of Montpellier, FR. Herbaux discussed the latest updates from the phase III STARGLO trial…
Lymphoma HubSymposium | Customizing therapy for MCL: Q&A
During the 18th International Conference on Malignant Lymphoma (ICML), June 17–21, 2025, Lugano, CH, the Lymphoma Hub held a symposium on June 17, 2025, titled…
Lymphoma HubSymposium | Current therapies for MCL and their combinations
During the 18th International Conference on Malignant Lymphoma (ICML), June 17–21, 2025, Lugano, CH, the Lymphoma Hub held a symposium on June 17, 2025, titled…
Lymphoma HubSymposium | Sequencing therapies and practical management of adverse events in MCL
During the 18th International Conference on Malignant Lymphoma (ICML), June 17–21, 2025, Lugano, CH, the Lymphoma Hub held a symposium on June 17, 2025, titled…
Lymphoma HubSymposium | Unmet needs in the treatment of MCL
During the 18th International Conference on Malignant Lymphoma (ICML), Jun 17–21, 2025, Lugano, CH, the Lymphoma Hub held a symposium on June 17, 2025, titled…
Lymphoma HubAnti-CD19 monoclonal antibodies for the treatment of DLBCL
During the Lymphoma Hub Steering Committee meeting, Grzegorz Nowakowski, the Mayo Clinic, Rochester, US, chaired a discussion on anti-CD19 monoclonal…
Lymphoma HubCELMoDs for the treatment of non-Hodgkin lymphoma
During the Lymphoma Hub Steering Committee Meeting, Gilles Salles, Memorial Sloan Kettering Cancer Center, New York, US, chaired a discussion on cereblon E3…
Lymphoma HubICML 2025 | What do the initial results from the LOTIS-7 trial suggest for loncastuximab tesirine plus glofitamab in R/R DLBCL?
During the 18th International Conference on Malignant Lymphoma (ICML), Jun 17–21, 2025, Lugano, CH, the Lymphoma Hub was pleased to speak with Juan Pablo…
Lymphoma HubWhat is the clinical significance of the long-term results from the EPCORE NHL-2 trial of epcoritamab + R-CHOP for previously untreated high-risk DLBCL?
During the 18th International Conference on Malignant Lymphomas (ICML), Jun 17–21, 2025, Lugano, CH, the Lymphoma Hub was pleased to speak with Joshua Brody…
Lymphoma HubEHA 2025 | What are the latest updates from the STARGLO trial of Glofit-GemOx vs R-GemOx in R/R DLBCL?
This educational resource is independently supported by Roche. All content is developed by SES in collaboration with an expert steering committee; funders are…
Lymphoma HubEHA 2025 | How effective is epcoritamab + R-ICE in patients with R/R DLBCL who are eligible for ASCT?
This educational resource is independently supported by AbbVie. All content is developed by SES in collaboration with an expert steering committee; funders are…
Lymphoma HubReal-world experience of tafasitamab and lenalidomide for the treatment of R/R DLBCL
The Lymphoma Hub was pleased to speak to Grzegorz S. Nowakowski, Mayo Clinic, Rochester, US, who discussed the real-world experience of tafasitamab and…
Lymphoma HubHow effective is the combination of tafasitamab and lenalidomide in treating R/R DLBCL?
This educational resource is independently supported by Incyte. All content is developed by SES in collaboration with an expert steering committee; funders are…
Lymphoma HubinMIND trial: Tafasitamab plus lenalidomide and rituximab for R/R FL
During the 66th American Society of Hematology (ASH) Meeting and Exposition, the Lymphoma Hub was pleased to speak to Stefano Luminari, University of Modena…
Lymphoma HubSymposium | Optimizing outcomes before and after CAR T-cell therapy in patients with large B-cell lymphoma
During the European Hematology Association (EHA) 2024 Hybrid Congress, the Lymphoma Hub and Multiple Myeloma Hub held a joint satellite symposium entitled…
Lymphoma HubSEQUOIA trial: Zanubrutinib + venetoclax in treatment-naïve patients with CLL/SLL
During the European Hematology Association (EHA) 2024 Hybrid Congress, the Lymphoma Hub was pleased to speak to Paolo Ghia, Vita-Salute San Raffaele, Milan…
Lymphoma HubSYMPHONY 1: A trial update
During the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the Lymphoma Hub spoke to Gilles Salles, Memorial Sloan Kettering Cancer…
Lymphoma HubNovel therapies in chronic lymphocytic leukemia: An update.
During the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the Lymphoma Hub spoke to Chan Cheah, University of Western Australia…
Lymphoma HubWhat are the CAR T-cell therapies on the horizon for lymphoma?
During the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the Lymphoma Hub spoke to Pere Barba, Hospital Universitari Vall d'Hebron…
Lymphoma HubHow do you choose among different BTK inhibitors for treating CLL?
The Lymphoma Hub was pleased to speak with Francesc Bosch, Vall d’Hebron Barcelona Hospital Campus, Barcelona, ES. We asked, How do you choose among different…
Lymphoma HubWhat are the latest advances in basal PET/CT for Hodgkin and non-Hodgkin lymphoma?
The Lymphoma Hub was pleased to speak with Astrid Pavlovsky, FUNDALEU, Buenos Aires, AR. We asked, What are the latest advances in basal PET/CT for Hodgkin and…
Lymphoma HubASCT in DLBCL – is it over?
As part of our biannual steering committee meeting, Gilles Salles, Memorial Sloan Kettering Cancer Center, New York, USA, chaired a discussion session on the…
Lymphoma HubWhat is on the horizon for the frontline treatment of MCL?
During the ASCO2022 congress, the Lymphoma Hub was pleased to speak with Anita Kumar, Memorial Sloane Kettering Cancer Center, New York, US. We asked, What is…
Lymphoma HubIs frontline R-CHOP still the standard of care for DLBCL?
During the 16th International Conference on Malignant Lymphoma (16-ICML), the Lymphoma Hub spoke with Laurie Sehn, The University of British Columbia…
Lymphoma HubWhat are the recent advances in antibody-drug conjugates for lymphoma treatment?
During the 2021 ASCO Annual Meeting, the Lymphoma Hub spoke with Catherine S. Diefenbach, Perlmutter Cancer Center, New York, US. We asked, What are the recent…
Lymphoma HubWhat is the role of genetic classification in the diagnosis of DLBCL?
During the 16th International Conference on Malignant Lymphoma (16-ICML), the Lymphoma Hub spoke with Björn Chapuy, Universitätsmedizin Göttingen, Göttingen…
Lymphoma HubWhat factors should be considered when deciding whether to refer a patient for CAR T-cell therapy?
During the EHA2021 Virtual Congress, the Lymphoma Hub spoke with Ulrich Jäger, Medical University of Vienna, Vienna, AT. We asked, What factors should be…
Lymphoma HubWhat does real-world data tell us about frontline treatment strategies for MCL?
During the 2021 ASCO Annual Meeting, the Lymphoma Hub spoke with Michael Wang, MD Anderson Cancer Center, Houston, US, and Peter Martin, Weill Cornell…
Lymphoma HubCan ctDNA help inform on the suitability of auto-SCT in patients with DLBCL?
This is the second episode in a series of podcasts following the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, on the topic of…
Lymphoma HubWhy should we use ctDNA assessments in lymphoma diagnostics in the future?
This is the first episode in a series of podcasts following the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, on the topic of…
Lymphoma HubDoes ctDNA add value to current prognostic markers for identifying high-risk patients?
This is the third episode in a series of podcasts following the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, on the topic of…
Lymphoma HubIs there a role for PET-CT-directed therapy in DLBCL?
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the Lymphoma Hub spoke to Judith Trotman, Concord Repatriation General…
Lymphoma HubCan we eliminate auto-SCT for patients with MCL?
During the European School of Haematology (ESH)'s 2nd How to Diagnose & Treat Lymphoma conference, the Lymphoma Hub spoke to Marco Ladetto, SS Antonio e Biagio…
Lymphoma HubCan we avoid chemotherapy entirely in follicular lymphoma?
During the European School of Haematology (ESH)'s 2nd How to Diagnose & Treat Lymphoma conference, the Lymphoma Hub spoke to Nathan Fowler, MD Anderson Cancer…
Lymphoma HubAn update in CLL from EHA 2020
During the 25th European Hematology Association (EHA) Annual Congress, the Lymphoma Hub spoke to Susan O'Brien, University of California Irvine, Orange, US…
Lymphoma HubHow can we use the microbiome to improve cancer immunotherapy and alleviate side effect such as graft-versus-host-disease
During the American Association of Cancer Research (AACR) Virtual Annual Meeting I, the Lymphoma Hub was pleased to speak to Christine Spencer, Parker…